United Therapeutics Corpo...
364.56
1.68 (0.46%)
At close: Jan 14, 2025, 3:59 PM
364.70
0.04%
After-hours Jan 14, 2025, 04:00 PM EST

United Therapeutics Corporation Statistics

Share Statistics

United Therapeutics Corporation has 44.64M shares outstanding. The number of shares has increased by -5.13% in one year.

Shares Outstanding 44.64M
Shares Change (YoY) n/a
Shares Change (QoQ) 0.34%
Owned by Institutions (%) n/a
Shares Floating 43.83M
Failed to Deliver (FTD) Shares 196
FTD / Avg. Volume 0.06%

Short Selling Information

The latest short interest is 2.24M, so 5.03% of the outstanding shares have been sold short.

Short Interest 2.24M
Short % of Shares Out 5.03%
Short % of Float 5.12%
Short Ratio (days to cover) 7.93

Valuation Ratios

The PE ratio is 10.45 and the forward PE ratio is 14.37. United Therapeutics Corporation's PEG ratio is 0.11.

PE Ratio 10.45
Forward PE 14.37
PS Ratio 4.42
Forward PS 4.8
PB Ratio 1.72
P/FCF Ratio 13.77
PEG Ratio 0.11
Financial Ratio History

Enterprise Valuation

United Therapeutics Corporation has an Enterprise Value (EV) of 9.78B.

EV / Earnings 9.93
EV / Sales 4.2
EV / EBITDA 7.05
EV / EBIT 8.26
EV / FCF 13.09

Financial Position

The company has a current ratio of 4.41, with a Debt / Equity ratio of 0.12.

Current Ratio 4.41
Quick Ratio 4.28
Debt / Equity 0.12
Total Debt / Capitalization 10.47
Cash Flow / Debt 1.4
Interest Coverage 19.98

Financial Efficiency

Return on equity (ROE) is 0.16% and return on capital (ROIC) is 13.7%.

Return on Equity (ROE) 0.16%
Return on Assets (ROA) 0.14%
Return on Capital (ROIC) 13.7%
Revenue Per Employee 1.99M
Profits Per Employee 843.15K
Employee Count 1.17K
Asset Turnover 0.32
Inventory Turnover 2.3

Taxes

Income Tax 289.50M
Effective Tax Rate 0.23

Stock Price Statistics

The stock price has increased by 66.68% in the last 52 weeks. The beta is 0.56, so United Therapeutics Corporation's price volatility has been higher than the market average.

Beta 0.56
52-Week Price Change 66.68%
50-Day Moving Average 370.84
200-Day Moving Average 324.7
Relative Strength Index (RSI) 50.92
Average Volume (20 Days) 326.98K

Income Statement

In the last 12 months, United Therapeutics Corporation had revenue of 2.33B and earned 984.80M in profits. Earnings per share was 21.04.

Revenue 2.33B
Gross Profit 2.07B
Operating Income 1.18B
Net Income 984.80M
EBITDA 1.39B
EBIT 1.18B
Earnings Per Share (EPS) 21.04
Full Income Statement

Balance Sheet

The company has 1.21B in cash and 700.00M in debt, giving a net cash position of 507.70M.

Cash & Cash Equivalents 1.21B
Total Debt 700.00M
Net Cash 507.70M
Retained Earnings 6.03B
Total Assets 7.12B
Working Capital 3.13B
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 978.00M and capital expenditures -230.40M, giving a free cash flow of 747.60M.

Operating Cash Flow 978.00M
Capital Expenditures -230.40M
Free Cash Flow 747.60M
FCF Per Share 15.97
Full Cash Flow Statement

Margins

Gross margin is 88.94%, with operating and profit margins of 50.91% and 42.31%.

Gross Margin 88.94%
Operating Margin 50.91%
Pretax Margin 54.75%
Profit Margin 42.31%
EBITDA Margin 59.58%
EBIT Margin 50.91%
FCF Margin 32.12%

Dividends & Yields

UTHR does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield 5.77%
FCF Yield 4.59%
Dividend Details

Analyst Forecast

The average price target for UTHR is $344, which is -5.6% lower than the current price. The consensus rating is "Strong Buy".

Price Target $344
Price Target Difference -5.6%
Analyst Consensus Strong Buy
Analyst Count 14
Stock Forecasts

Stock Splits

The last stock split was on Sep 23, 2009. It was a forward split with a ratio of 2:1.

Last Split Date Sep 23, 2009
Split Type forward
Split Ratio 2:1

Scores

Altman Z-Score 12.25
Piotroski F-Score 8